Search for: "In re: Wellbutrin XL Antitrust Litigation"
Results 1 - 6
of 6
Sorted by Relevance
|
Sort by Date
30 May 2012, 6:56 pm
District Court for the Eastern District of Pennsylvania in In re Wellbutrin XL Antitrust Litigation, the court once again tackled the issues of “sham” citizen petitions, liability under the Sherman Antitrust Act, and Noerr-Pennington immunity. [read post]
13 Mar 2014, 2:11 pm
In so limiting the potential class, the court, writing without benefit of binding Third Circuit precedent, adopted the standing analysis of the Eastern District of Pennsylvania in In re Wellbutrin XL Antitrust Litig., 260 F.R.D. 143 (E.D. [read post]
27 Aug 2017, 10:01 pm
See In re Wellbutrin XL Antitrust Litig., No. 15-2875 (3d Cir. [read post]
27 Aug 2017, 10:01 pm
See In re Wellbutrin XL Antitrust Litig., No. 15-2875 (3d Cir. [read post]
3 Jun 2010, 5:35 am
(Spicy IP) Wellbutrin (Bupropion) – US: Pennsylvania District Court decision signals a new turn in the generic drug preemption debate; a tough pill to swallow for the generic industry: In re Budeprion XL Marketing & Sales Litigation (FDA Law Blog) [read post]
29 Feb 2008, 8:00 am
– Teva’s opposition proceedings regarding IL 130424 to Pfizer: (IP Factor), Thailand: Thai chief drug price negotiator removed from post: (GenericsWeb), Thailand: Compulsory licences cannot be revoked: (Generic Pharmaceuticals & IP), (more from Generic Pharmaceuticals & IP), UK: Court of Appeal for England and Wales hands down decision in Boehringer Ingelheim KG and Boehringer Ingelheim Pharma KG v Swingward Limited relating to repackaging and de-branding of… [read post]
